首页|miR-135b在消化系统恶性肿瘤中的研究现状

miR-135b在消化系统恶性肿瘤中的研究现状

扫码查看
微小RNA(microRNA、miRNA)是一类内源性、单链、短而高度保守的非编码RNA.miR-135b作为miRNA中的一员,在消化系统恶性肿瘤中异常表达.其作用机制涉及多种靶基因,通过调控细胞增殖、转移、耐药等参与肿瘤的发生和发展.miR-135b的高表达与患者预后不良和生存率下降相关联.作为潜在的生物标志物,miR-135b可能有助于消化系统恶性肿瘤的诊断、预后评估和治疗监测.因此,miR-135b及其调控的通路可能成为未来治疗的靶点,为肿瘤患者的治疗和管理提供新的思路.
Research status of miR-135b in malignant tumors of the digestive system
MicroRNAs(microRNAs,miRNAs)are a class of endogenous,single-stranded,short and highly conserved non-coding RNAs.miR-135b,as a member of miRNAs,is aberrantly expressed in digestive malignancies.Its mechanism of action involves a variety of target genes and participates in tumorigenesis and development by regulating cell proliferation,metastasis,and drug resistance.Clinical studies have shown that high expression of miR-135b is associated with poor patient prognosis and decreased survival.As a potential biomarker,miR-135b may be useful in the diagnosis,prognostic assessment,and therapeutic monitoring of malignant tumors of the digestive system.Therefore,miR-135b and its regulated pathways may become future therapeutic targets and provide new ideas for the treatment and management of tumor patients.

microRNAmicroRNA-135btumors of the digestive system

何钰洁、陈佳、夏琪、陈文、殷佩浩

展开 >

成都中医药大学医学与生命科学学院,四川成都 610075

上海中医药大学附属普陀医院中西医结合肿瘤介入研究所 上海 200062

微小RNA miRNA-135b 消化系统肿瘤

上海市普陀区卫生健康系统临床特色专科建设基金资助项目上海中医药大学科技发展基金资助项目

2021tszk0123kfl084

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(18)
  • 3